Heartland Advisors Inc. Sells 73,764 Shares of Perrigo Company plc $PRGO

Heartland Advisors Inc. reduced its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 32.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 150,219 shares of the company’s stock after selling 73,764 shares during the period. Heartland Advisors Inc.’s holdings in Perrigo were worth $1,613,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Amundi boosted its position in shares of Perrigo by 11.7% during the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after purchasing an additional 556 shares in the last quarter. Kestra Investment Management LLC grew its stake in Perrigo by 57.1% during the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after purchasing an additional 642 shares during the period. Geneos Wealth Management Inc. increased its holdings in Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Perrigo by 116.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after purchasing an additional 1,014 shares in the last quarter. Finally, Covestor Ltd lifted its stake in Perrigo by 14.4% in the fourth quarter. Covestor Ltd now owns 8,991 shares of the company’s stock valued at $125,000 after buying an additional 1,129 shares during the period. 95.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on PRGO. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $19.33.

Perrigo Stock Up 0.1%

PRGO stock opened at $10.73 on Monday. The stock’s 50 day simple moving average is $10.66 and its 200 day simple moving average is $11.90. Perrigo Company plc has a fifty-two week low of $9.23 and a fifty-two week high of $28.43. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. The company has a market cap of $1.48 billion, a P/E ratio of -0.82, a price-to-earnings-growth ratio of 1.27 and a beta of 0.51.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The business had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the prior year, the company earned $0.60 earnings per share. The company’s quarterly revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, research analysts expect that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Friday, May 29th were issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.8%. The ex-dividend date was Friday, May 29th. Perrigo’s dividend payout ratio (DPR) is currently -8.85%.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.